



24 October 2019

ASX ANNOUNCEMENT

ImpediMed Quarterly Results and Investor Conference Call

Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD) advises it will release its Appendix 4C Cash Flow Statement and Quarterly Results for the period ending 30 September 2019, on Wednesday 30 October 2019.

Investors are invited to join a conference call with Managing Director and CEO, Richard Carreon at **9.15am AEDT on Wednesday 30 October 2019**.

To pre-register please follow this link:

<https://s1.c-conf.com/diamondpass/impedimed-10002561-invite.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call.

Richard Carreon
Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a software medical technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.